At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. 

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease.

Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.

As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease.

To learn more please visit www.hookipapharma.com. 


Biotechnology

Life Sciences

Pharmaceutical

HOOKIPA Pharma Inc.

Klaus Orlinger

Reinhard Kandera

Roland Bauer

Mark McKechnie

Roman Necina

Aidan Finley

Reischer Nicolas

Susan Trinker

Anastasiia Bazhan

Bernhard Binder

Leadership Team

Quality and Supply Chain Team

Research and Development

Finance Team

Teams at HOOKIPA Pharma Inc.

Leadership Team

Quality and Supply Chain Team

Research and Development

Finance Team